A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis

"During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~1. Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~2. Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~3. Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days."